Revenue segments as reported by the company.

Product sales

Royalty, contract and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development expenses

Selling, general and administrative

In-process research and development impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Gilead Sciences reports robust earnings, eyes pipeline opportunities for growth

Gilead Sciences delivered strong financial performance in Q4 2022, driven by growth in key product sales. Despite facing challenges in the HIV market for Q1 2023, the company remains focused on leveraging opportunities in its pipeline and strategic investments.

Gilead reports strong Q1 sales, focuses on pipeline growth

Gilead Sciences delivered strong sales driven by key products in Q1 2023.
While facing challenges like lower Veklury sales, Gilead maintains revenue guidance.
The company's strengths lie in its pipeline, successful products, and manufacturing capabilities.
Opportunities in new indications and therapies position Gilead for future growth.

Gilead Sciences reports robust Q2 performance and eyes future growth

Gilead Sciences had a strong quarter with growth in sales and positive pipeline updates.
Trodelvy's performance in different markets and potential Medicare coverage are key highlights.
Challenges include unsuccessful trials and addressing revenue aspirations.
Opportunities lie in expanding BD activities and exploring cell therapy beyond oncology.

Gilead Sciences reports robust Q3 performance amidst market challenges

Gilead Sciences demonstrated strong performance in Q3 2023, driven by growth in base business, oncology, and HIV segments.
While facing challenges such as declining Veklury sales and barriers to CART therapy uptake, Gilead is actively addressing opportunities for growth and market expansion.
The company's strengths lie in robust product sales, particularly in Biktarvy and Trodelvy, with a focus on innovation and strategic positioning in key therapeutic areas.
Overall, Gilead's performance reflects resilience and strategic planning amidst evolving market dynamics and competitive landscapes.

Gilead Sciences reports strong 2023 performance, eyes transformative therapies

Gilead Sciences showcased solid performance in 2023 with notable growth in key product sales areas, despite facing challenges in certain clinical trials. The company's strengths lie in its diverse portfolio, pipeline innovation, and commitment to delivering transformative therapies. With a focus on addressing HIV, oncology, and inflammation, Gilead is well-positioned for future growth and success.

Gilead Sciences reports robust Q1 performance and eyes future growth

Gilead Sciences delivered strong Q1 results driven by oncology and HIV product sales.
Challenges include IP R&D charge from Sema Bay acquisition and competitive market dynamics.
Opportunities lie in expanding cell therapy leadership, advancing HIV pipeline, and upcoming pipeline updates.
Overall, Gilead remains focused on growth through innovation and strategic portfolio advancements.

Gilead Sciences reports robust Q3 performance and eyes market expansion

Gilead Sciences' Q3 performance reflects strong revenue growth and market leadership in key segments, supported by successful product launches and strategic initiatives.
The company's focus on innovation, patient-centric approaches, and market expansion bodes well for future growth and competitive positioning.
While challenges in maintaining growth and managing expenses exist, Gilead's proactive stance on addressing market needs and leveraging opportunities positions it for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Gilead Sciences Inc on Thursday posted higher second-quarter earnings, helped by strong sales of its COVID-19 antiviral treatment, Veklury, as well as hepatitis drugs.

Strong COVID-19 drug sales help boost Gilead second-quarter results

FOSTER CITY, Calif.--(BUSINESS WIRE)---- $GILD #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the second quarter 2021. “We maintained our positive momentum in the second quarter, with both a solid financial performance and strong progress across our increasingly diverse portfolio. Our flagship HIV therapy, Biktarvy, saw continued growth and gains in market share, despite the ongoing impact of the pandemic,” said Daniel O'Day, Chairman and Chief Executive Officer, Gile

Gilead Sciences Announces Second Quarter 2021 Financial Results

Investors will focus on the HIV franchise's performance and Veklury sales when Gilead (GILD) reports second-quarter 2021 results.

Gilead (GILD) to Report Q2 Earnings: What's in the Cards?

Gilead Sciences Inc. (NYSE: GILD) was ordered to pay about $1.8 million late last week in attorney's fees and legal expenses to shareholders who sued the company after they were blocked from reviewing notable company records, according to Courthouse News Service.  Why It Matters: The information requests initially stemmed from the company using licensing agreements with rivals to slow generic competition to its HIV prevention drug.

Gilead Ordered To Pay Attorney Fees In Shareholder Lawsuit

AbbVie

Amgen

Bristol-Myers

Fidelity MSCI Health Care ETF

iShares U.S. Healthcare ETF

Johnson & Johnson

Merck

Pfizer

Thermo Fisher Scientific

UnitedHealth Group

Vanguard Health Care ETF

Health Care Select Sector SPDR Fund

The healthcare sector has been benefiting from COVID-19 vaccines or treatment with many more to come.

Healthcare ETFs in Focus as Q2 Earnings Unfold

Eli Lilly

Vertex Pharmaceuticals

They have ample motivation and cash to gobble up a smaller company.

3 Biotechs That Could Make Big Acquisitions This Year

BioNTech SE

Shares of BioNTech SE were down 2.4% in premarket trading on Monday after the company said it plans to buy one of Gilead Sciences Inc.'s clinical manufacturing facilities and its platform for T-cell receptor therapies. The companies did not disclose financial terms of the deal, saying only that BioNTech will make a one-time payment for the platform and the facility in Gaithersburg, MD.

BioNTech to buy T-cell receptor facility and platform from Gilead Sciences

MAINZ, Germany & SANTA MONICA, Calif.--(BUSINESS WIRE)--BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Kite, a Gilead Company (Nasdaq: GILD, “Kite”) today announced the two companies have entered into a purchase agreement for BioNTech to acquire Kite's solid tumor neoantigen T cell receptor (TCR) R&D platform and clinical manufacturing facility in Gaithersburg, MD. The acquired Gaithersburg facility will provide production capacity to support clinical trials in the United States and will comple

BioNTech to Acquire Kite's Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, MD

Gilead Sciences Inc (NASDAQ: GILD) announced new Phase 3 data from the ongoing CAPELLA trial evaluating lenacapavir, its investigational, long-acting HIV-1 capsid inhibitor.  The data were presented at the 11th International AIDS Society (IAS) Conference on HIV Science.

Gilead's Lenacapavir Shows High Rates Of Virologic Suppression In Heavily Treated HIV Patients

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced a pooled analysis of a 48-week open-label extension of two Phase 3 studies (Study 1489 and Study 1490) shows 99% of participants who initiated treatment with Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) maintained an undetectable viral load (HIV-1 RNA

Four-Year Biktarvy® Data Presented at IAS 2021 Demonstrate High Efficacy and Durable Viral Suppression in Treatment-Naïve Adults

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced new results from the ongoing Phase 2/3 CAPELLA trial evaluating lenacapavir, the company's investigational, long-acting HIV-1 capsid inhibitor, in heavily treatment-experienced people living with multi-drug resistant HIV. The findings demonstrate that lenacapavir, administered subcutaneously every six months in combination with other antiretrovirals, achieved high rates of virologic suppression at Week 26

New Phase 3 Data Support the Sustained, Long-Acting Efficacy of Lenacapavir, Gilead's Investigational HIV-1 Capsid Inhibitor

British American Tobacco

Medical Properties Trust

Safe high-yielding stocks can be found in both bull and bear markets alike. I present 3 picks that offer safety, growth, and diversification, as they reside in three vastly different sectors.

3 High Dividends I'm Buying Hand Over Fist

FOSTER CITY, Calif.--(BUSINESS WIRE)---- $GILD #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2021 financial results will be released on Thursday, July 29, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's second quarter 2021 financial results and will provide a business update. A live webcast will be available on the investor relations page of http://investors.gilead.com and will be archived on www

Gilead Sciences to Release Second Quarter 2021 Financial Results on Thursday, July 29, 2021

Altria

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

And there's a good chance you could be earning even more than that.

Investing $72,036 Into These 3 Stocks Can Generate $300 in Monthly Income for Your Portfolio

According to a study published in the Annals of Internal Medicine, neither Gilead Sciences Inc's (NASDAQ: GILD) Veklury (remdesivir) nor hydroxychloroquine (HCQ) did significantly clear the virus from hospitalized COVID-19 patients or affect the degree of respiratory failure and inflammation over the standard of care after ten days. Between 28 March and 4 October 2020, 185 patients were randomly assigned, and 181 were included in the full analysis set.

Gilead's Remdesivir Fails To Show Antiviral Effects Against COVID-19 In Small WHO Study

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the company's upcoming contributions to the 11th International AIDS Society (IAS) Conference on HIV Science, taking place virtually from July 18-21. Thirty-one abstracts reflect Gilead's ongoing commitment to scientific innovation, a key pillar to addressing unmet needs in HIV treatment and prevention. Beyond presenting new scientific data from the company's HIV research and development programs, Gilead w

Gilead to Present New Data at IAS 2021 Demonstrating the Company's Commitment to Advancing Innovation in HIV Research

In a recent article, we highlighted a list of large-cap, high-quality dividend stocks with the ability to produce stable option income over the next 12 months. This article is part of a series that will individually cover some of our favorite stocks from that list.

Gilead: Great For Covid And Your Income Portfolio

Amazon

Alibaba

General Mills

Alphabet

Henkel AG & Co KGaA

Reckitt Benckiser Group PLC

Tencent Holdings Limited

Walgreens

The stock market is overvalued, but we can still try to find investments without overpaying. A first category of stocks are recession-proof and undervalued companies like Walgreens Boots Alliance, Henkel, Amgen or AbbVie.

10 Picks For July

Clorox

Cabot Oil & Gas

Quest Diagnostics

Hologic

Labcorp Holdings Inc

PerkinElmer

Regeneron Pharmaceuticals

Texas Instruments

The shares of these S&P 500 companies are not only priced right—they also could hold up better during volatility.

11 Quality Stocks That Are Relatively Cheap

Gilead (GILD) maintains momentum in the year so far on the back of Veklury for the treatment of COVID-19 and the same is expected to continue in the second half.

Gilead (GILD) Gains 19% YTD: What to Expect in The Second Half?

Gilead (GILD) announces results from the ZUMA-7 study on Yescarta and completes submission of application to the FDA seeking approval of lenacapavir.

Gilead's (GILD) Kite Announces Positive Data on Yescarta

Pardes Biosciences Inc, an early-stage biopharmaceutical company, and FS Development Corp. II (NASDAQ: FSII), a Foresite Capital sponsored SPAC, entered into a definitive merger agreement. Pardes Biosciences was founded at the beginning of 2020 by Uri Lopatin, a former Gilead executive who co-founded and served as CMO of Assembly Biosciences.

Gilead, Foresite Take Pardes Biosciences Public In $250M SPAC Deal

bluebird bio

Legend Biotech

Legend Biotech's CAR-T therapy's trial results were amazing, and could earn the treatment FDA approval in 2021.

Will This 2020 Biotech IPO Crush the Market This Year?

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that the company completed submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor, for the treatment of HIV-1 infection in heavily treatment-experienced (HTE) people with multi-drug resistant (MDR) HIV-1 infection. The submission is supported by data from the Phase 2/3 CAPELLA trial,

Gilead Submits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting Capsid Inhibitor for the Treatment of HIV-1 in People With Limited Therapy Options

Gilead Sciences Inc's (NASDAQ: GILD) unit Kite Pharma has announced top-line results from the primary analysis of ZUMA-7 of Yescarta (axicabtagene ciloleucel) compared to standard of care (SOC) in second-line relapsed or refractory large B-cell lymphoma (LBCL). Yescarta boosted event-free survival (EFS) over a standard of care regimen of physicians'-choice therapy followed by high-dose chemo plus a stem cell transplant.

News for Gilead Sciences Stock (GILD)